DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies-Reference-Cited by-同舟云学术

DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies

Published:2015-09-10 Issue:32 Volume:6 Page:32494-32508
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Le Pogam Carole¹²,Patel Satyananda¹²,Gorombei Petra¹²,Guerenne Laura¹²,Krief Patricia¹²,Omidvar Nader³,Tekin Nilgun⁴,Bernasconi Elena¹²,Sicre Flore¹²⁵,Schlageter Marie-Helene¹²⁵,Chopin Martine⁶,Noguera Maria-Elena⁵,West Robert⁷,Abu Ansu⁸,Mathews Vikram⁸,Pla Marika¹²,Fenaux Pierre¹²⁵,Chomienne Christine¹²⁵,Padua Rose Ann¹²⁵

Affiliation:

1. Unité Mixte de la Recherche de Santé (UMR-S), Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France

2. Institut National de la Santé et de la Recherche Médicale (INSERM) Unité (U), Paris, France

3. Haemotology Department, Cardiff University School of Medicine, Cardiff, UK

4. Biotechnology Institute, Ankara University, Ankara, Turkey

5. Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

6. Département d'Expérimentation Animale, Institut Universitaire d'Hématologie, University Paris Diderot, Paris, France

7. Welsh Heart Research Institute, Cardiff University School of Medicine, Cardiff, UK

8. Department of Hematology, Christian Medical College and Hospital, Vellore, India

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-Associated Antigens;Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation;2019

2. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival;Scientific Reports;2017-10-24

3. GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways;Journal of Hematology & Oncology;2016-01-27

4. pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice;Blood Cancer Journal;2015-12